Loading clinical trials...
Loading clinical trials...
Individual and Combined Endothelin Receptor and SGLT2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over Trial
Conditions
Interventions
Dapagliflozin (Forxiga®)
SC0062 strength 10mg
+1 more
Locations
7
Denmark
Steno Diabetes Center Aarhus
Aarhus, Denmark
Steno Diabetes Center Copenhagen
Copenhagen, Denmark
Regionshospitalet Gødstrup
Herning, Denmark
University of Helsinki
Helsinki, Uusimaa, Finland
Turku University Hospital
Turku, Finland
Amsterdam University Academic Center
Amsterdam, North Holland, Netherlands
Start Date
January 1, 2026
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2028
Last Updated
October 7, 2025
Lead Sponsor
University Medical Center Groningen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions